Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 as a Single Agent and in Combination With Azacitidine in Patients With Relapsed or Refractory Hematologic Malignancies

Next Previous
Trial Profile

A Phase 1/1b Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 as a Single Agent and in Combination With Azacitidine in Patients With Relapsed or Refractory Hematologic Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CC 95775 (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors FORMA Therapeutics; Novo Nordisk

    • Most Recent Events

    • 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 25 Jun 2019 Status changed from recruiting to completed.
    • 14 Feb 2018 Azacitidine drug has added in the study hence treatment arms and patients numbers are increases. study design has also changed from single assignment to parallel.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top